Content
03/05/2025 Cambridge United Kingdom
TRIMTECH Therapeutics completed $31 million Seed Round funding. Investors include SV Health Investors (lead), Cambridge Innovation Capital (lead), M Ventures, Pfizer Ventures, Eli Lilly and Company, MP Healthcare Venture Management, Cambridge Enterprise Ventures.
#Biotech  #Life Science  
About
TRIMTECH has a growing pipeline of potent, CNS (central nervous system) penetrant therapeutics based on its aggregate-selective degrader molecules known as TRIMTACs and TRIMGLUEs. The pipeline is focused around the development of treatments for severe neurodegenerative and inflammatory disorders, including Alzheimer’s and Huntington’s disease.
Startup
TRIMTECH Therapeutics
https://trimtechtherapeutics.com Claim Profile
Location:
Cambridge United Kingdom
Sector:
Biotech
Life Science
Download StockFan App Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.